Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph not_applicable
2
40%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
3(60.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 33 (60.0%)
N/A2 (40.0%)

Trials by Status

completed360%
not_yet_recruiting240%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingnot_applicable

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

NCT07349797
not_yet_recruitingnot_applicable

Evaluation of Protein Loading on Measurement of Renal Reserve

NCT07335614
completedphase_3

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

NCT05777174
completedphase_3

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

NCT05425719
completedphase_3

A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants

NCT05943977

Clinical Trials (5)

Showing 5 of 5 trials
NCT07349797Not Applicable

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

Not Yet Recruiting
NCT07335614Not Applicable

Evaluation of Protein Loading on Measurement of Renal Reserve

Not Yet Recruiting
NCT05777174Phase 3

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

Completed
NCT05425719Phase 3

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

Completed
NCT05943977Phase 3

A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants

Completed

All 5 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
5